Association of miR-21-5p, miR-122-5p, and miR-320a-3p with 90-Day Mortality in Cardiogenic Shock.
cardiogenic shock
microRNA
mortality
prognosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Oct 2020
26 Oct 2020
Historique:
received:
29
09
2020
revised:
20
10
2020
accepted:
22
10
2020
entrez:
29
10
2020
pubmed:
30
10
2020
medline:
4
3
2021
Statut:
epublish
Résumé
Cardiogenic shock (CS) is a life-threatening emergency. New biomarkers are needed in order to detect patients at greater risk of adverse outcome. Our aim was to assess the characteristics of miR-21-5p, miR-122-5p, and miR-320a-3p in CS and evaluate the value of their expression levels in risk prediction. Circulating levels of miR-21-5p, miR-122-5p, and miR-320a-3p were measured from serial plasma samples of 179 patients during the first 5-10 days after detection of CS, derived from the CardShock study. Acute coronary syndrome was the most common cause (80%) of CS. Baseline (0 h) levels of miR-21-5p, miR-122-5p, and miR-320a-3p were all significantly elevated in nonsurvivors compared to survivors (
Identifiants
pubmed: 33114482
pii: ijms21217925
doi: 10.3390/ijms21217925
pmc: PMC7662780
pii:
doi:
Substances chimiques
Biomarkers
0
MIRN122 microRNA, human
0
MIRN21 microRNA, human
0
MIRN320 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Rev Esp Cardiol (Engl Ed). 2019 Sep;72(9):783-786
pubmed: 30471962
Cell Mol Biol Lett. 2018 Aug 28;23:41
pubmed: 30181740
Circulation. 2017 Oct 17;136(16):e232-e268
pubmed: 28923988
J Clin Med. 2020 Apr 08;9(4):
pubmed: 32276307
Circulation. 2009 May 5;119(17):2357-2366
pubmed: 19380620
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Circ J. 2016 Sep 23;80(10):2183-91
pubmed: 27593229
J Clin Invest. 2012 Aug;122(8):2884-97
pubmed: 22820290
Eur Heart J. 2015 May 21;36(20):1223-30
pubmed: 25732762
J Am Coll Cardiol. 2020 Apr 21;75(15):1788-1800
pubmed: 32299591
Carcinogenesis. 2014 Apr;35(4):886-95
pubmed: 24265291
Clin Chem. 2010 Dec;56(12):1830-8
pubmed: 20930130
Eur J Heart Fail. 2015 May;17(5):501-9
pubmed: 25820680
Curr Biol. 2002 Apr 30;12(9):735-9
pubmed: 12007417
Shock. 2012 Feb;37(2):234-8
pubmed: 22089187
Bratisl Lek Listy. 2018;119(6):341-347
pubmed: 29947233
Cardiology. 2011;118(4):217-26
pubmed: 21701171
N Engl J Med. 2012 Oct 4;367(14):1287-96
pubmed: 22920912
Adv Drug Deliv Rev. 2015 Jun 29;87:3-14
pubmed: 25979468
Eur Heart J. 2010 Mar;31(6):659-66
pubmed: 20159880
Circ Res. 2012 Feb 3;110(3):483-95
pubmed: 22302755
Thromb Haemost. 2012 Oct;108(4):592-8
pubmed: 22627831
Eur J Heart Fail. 2018 Mar;20(3):572-581
pubmed: 28960633
Int J Mol Sci. 2020 Jan 21;21(3):
pubmed: 31973111
Oncotarget. 2016 May 17;7(20):29275-86
pubmed: 27086911
Cardiovasc Res. 2010 Aug 1;87(3):431-9
pubmed: 20219857
Biomarkers. 2019 Feb;24(1):29-35
pubmed: 30015516
J Biol Chem. 2009 Oct 23;284(43):29514-25
pubmed: 19706597
Eur Heart J Acute Cardiovasc Care. 2018 Feb;7(1):38-44
pubmed: 28403620
FEBS Lett. 2014 Aug 25;588(17):3137-46
pubmed: 24983504
Clin Chem. 2012 Mar;58(3):559-67
pubmed: 22252325
Cancer Lett. 2017 Jul 1;397:33-42
pubmed: 28288874
Med Sci Monit. 2017 Dec 02;23:5728-5734
pubmed: 29197221
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Intern Med. 2015 Feb;277(2):260-271
pubmed: 24345063
Circulation. 2008 Feb 5;117(5):686-97
pubmed: 18250279
J Am Coll Cardiol. 2000 Sep;36(3 Suppl A):1063-70
pubmed: 10985706
Circ Cardiovasc Genet. 2010 Dec;3(6):499-506
pubmed: 20921333
Clin Chim Acta. 2019 Dec;499:98-107
pubmed: 31499022
Cells. 2019 Aug 19;8(8):
pubmed: 31430983
RNA Biol. 2011 Sep-Oct;8(5):706-13
pubmed: 21712654
Nephrol Dial Transplant. 2011 Nov;26(11):3794-802
pubmed: 21891774
ESC Heart Fail. 2019 Feb;6(1):98-102
pubmed: 30472788
J Cardiovasc Transl Res. 2010 Jun;3(3):251-5
pubmed: 20560046